Via News Knowledge File

Novo Nordisk A/S

organization80% conf.·synced Aug 13, 2026

Pharmaceutical manufacturer of Wegovy (semaglutide) for weight management

sourced metrics

640

relationships

stated objectives

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Return Ytd

-11.5%

Aug 12, 2026reference only

Price 52 Week High

63.98USD

Aug 12, 2026reference only

Price 52 Week Low

35.29USD

Aug 12, 2026reference only

Stock Price

46.39USD

Aug 12, 2026reference only

Market Presence Countries

170countries

May 12, 2026source

Employee Presence Countries

80countries

May 12, 2026source

Free Cash Flow

52100000000.0DKK

Apr 1, 2026source

Year To Date Return

-29.4percent

Apr 1, 2026source

30 Day Return

0.9percent

Apr 1, 2026source

Valuation Score

5out_of_6

Apr 1, 2026source

7 Day Return

1.6percent

Apr 1, 2026source

Projected Free Cash Flow 2030

111.09billion_DKK

Apr 1, 2026source

Discount To Intrinsic Value

65.2percent

Apr 1, 2026source

1 Year Return

-43.1percent

Apr 1, 2026source

Intrinsic Value Dcf

106.21USD

Apr 1, 2026source

Final Dividend Per Share

7.95DKK

Mar 26, 2026source

Dividend Per Share

11.70DKK

Mar 26, 2026source

Share Par Value

0.10DKK

Mar 26, 2026source

Stated objectives

Make Wegovy pill affordable and accessible to those who need it across multiple care channels

source

target: 70000+ US pharmacies by 2026-01-05 00:00:00stated

Provide affordable starting dose of Wegovy pill for self-pay patients

source

target: $149 per month ($5 per day) by 2026-01-05 00:00:00stated

Sales decline of 5% to 13% in 2026

source

target: -5% to -13% by 2026-12-31 00:00:00stated

Launch oral Wegovy formulation through pharmacies and telehealth providers

source

by 2026-01-01 00:00:00stated

Launch oral Wegovy pill in U.S. market

source

target: full_market_launch by 2026-01-01 00:00:00stated

Full U.S. launch of oral semaglutide in early January 2026

source

by 2026-01-01 00:00:00stated

Claw back ground lost to US rival Eli Lilly in weight-loss drug market

source

stated

Adjusted operating profit growth decline of 5% to 13% in 2026

source

target: -5% to -13% by 2026-12-31 00:00:00stated

2026 sales expected to fall

source

by 2026-12-31 00:00:00stated

Complete Phase III development of Ziltivekimab for inflammation-associated cardiovascular disease

source

stated

Relationship graph · 640 connections

Developed by

242

Competes with

129

Employs

regulates

headquartered in

Supplies to

Covered by

rates

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →